Searchable abstracts of presentations at key conferences in endocrinology

ea0026oc4.5 | Diabetes/Thyroid | ECE2011

Comparison of four strategies of radioiodine ablation in patients with thyroid cancer with low-risk of recurrence: the randomized, prospective ESTIMABL study

Leenhardt L , Catargi B , Borget I , Zerdoud S , Bridji B , Bardet S , Toubert M E , Schlumberger M

Objective: The objective of this clinical trial is to compare four strategies of management of postoperative radioiodine ablation in a 2×2 factorial design, each strategy combining a method of TSH stimulation and an activity of 131I. The primary endpoint is the rate of thyroid ablation.Patients and methods: This multicentric, randomized, controlled, phase III trial involved 24 French centers, and compared 4 strategies for postoperative radioiodine a...

ea0029oc9.1 | Endocrine Tumours & Translation | ICEECE2012

The Young Investigator Winner

Hadoux J. , Leboulleux S. , Al Ghuzlan A. , Borget I. , Caramella C. , Chougnet C. , Young J. , Dumont F. , Deschamps F. , Schlumberger M. , Baudin E.

Malignant pheochromocytoma and paraganglioma (PPGLs) are rare diseases with a heterogeneous behaviour. 131I-MIBG therapy and the cyclophosphamide-dacarbazine-vincristine chemotherapy regimen (CVD) constitute the most popular options in the metastatic setting. We have investigated the antitumor effect of temozolomide (TMZ), in patients with metastatic PPGLs. Efficacy was primary endpoint, safety and identification for prognosis factors of response were secondary endpoints.<...

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage IIIĀ–ENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...